Symbols / JAGX Stock $0.38 -2.87% Jaguar Health, Inc.

Healthcare • Biotechnology • United States • NCM
JAGX (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Ms. Lisa A. Conte
Exch · Country NCM · United States
Market Cap 4.99M
Enterprise Value 48.86M
Income -53.58M
Sales 11.51M
FCF (ttm) -14.62M
Book/sh -2.83
Cash/sh 0.07
Employees 47
Insider 10d —
IPO May 12, 2015
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -0.07
PEG —
P/S 0.43
P/B -0.14
P/C —
EV/EBITDA -1.13
EV/Sales 4.25
Quick Ratio 0.07
Current Ratio 0.50
Debt/Eq —
LT Debt/Eq —
EPS (ttm) -22.97
EPS next Y -5.68
EPS Growth —
Revenue Growth -7.80%
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-05-14
Earnings (prior) 2025-11-14
ROA -61.46%
ROE —
ROIC —
Gross Margin 67.21%
Oper. Margin -6.32%
Profit Margin 0.00%
Shs Outstand 13.02M
Shs Float 12.09M
Insider Own 10.34%
Instit Own 0.50%
Short Float 3.88%
Short Ratio 1.01
Short Interest 481.25K
52W High 15.48
vs 52W High -97.53%
52W Low 0.31
vs 52W Low 22.40%
Beta 0.29
Impl. Vol. —
Rel Volume 0.42
Avg Volume 514.86K
Volume 217.09K
Target (mean) $7.50
Tgt Median $7.50
Tgt Low $7.50
Tgt High $7.50
# Analysts 1
Recom None
Prev Close $0.39
Price $0.38
Change -2.87%
About

Jaguar Health, Inc., a commercial-stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress. The company operates through two segments, Animal Health and Human Health. It focuses on developing and commercializing prescription and non-prescription products for companion and production animals; and human products. The company offers Mytesi, an anti-secretory antidiarrheal drug for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy; and Canalevia-CA1, a prescription drug product for chemotherapy-induced diarrhea in dogs. It is also developing Crofelemer, an anti-secretory antidiarrheal drug, which is in Phase III clinical trial for prophylaxis of diarrhea in adult cancer patients; Phase II clinical trials for rare/orphan disease indications, including short bowel syndrome with intestinal failure and microvillus inclusion disease; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, the company is developing Mytesi which is in Phase III clinical trial for cancer therapy-related diarrhea, as well as Phase II clinical trial for irritable bowel syndrome; and NP-300, a second-generation antidiarrheal drug that is in Phase I clinical trial for symptomatic relief and treatment of moderate-to-severe diarrhea. The company is headquartered in San Francisco, California.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$7.50
Mean price target
2. Current target
$0.38
Latest analyst target
3. DCF / Fair value
$-20.21
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.38
Low
$7.50
High
$7.50
Mean
$7.50

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2025-05-19 init First Berlin — → Buy $60
News
RSS: Latest JAGX news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2025-12-11 BOCHNOWSKI JAMES J. Director — 6,363 $0.00 $0
2025-12-11 MICEK JOHN J III Director — 7,377 $0.00 $0
2025-12-11 KING STEVEN R. PH.D. Officer — 11,740 $0.00 $0
2025-12-11 CONTE LISA A. Chief Executive Officer — 28,592 $0.00 $0
2025-12-11 SIEGEL JONATHAN B Director — 7,377 $0.00 $0
2025-12-11 LIZAK CAROL R. Chief Financial Officer — 11,740 $0.00 $0
2025-12-11 WOLIN JONATHAN S General Counsel — 11,740 $0.00 $0
2025-12-11 JAYASURIYA ANULA Director — 5,870 $0.00 $0
2025-12-11 CHATURVEDI PRAVIN R Officer — 11,740 $0.00 $0
2025-05-16 KING STEVEN R. PH.D. Officer — 1 — —
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
11.51
-1.52%
11.69
+19.75%
9.76
-18.36%
11.96
Operating Revenue
15.50
-0.56%
15.58
+14.53%
13.61
-9.40%
15.02
Cost Of Revenue
3.77
+93.04%
1.96
-4.03%
2.04
+0.89%
2.02
Reconciled Cost Of Revenue
3.43
+138.69%
1.44
-29.46%
2.04
+0.89%
2.02
Gross Profit
7.74
-20.52%
9.73
+26.02%
7.72
-22.27%
9.94
Operating Expense
52.84
+30.27%
40.56
-2.59%
41.64
-6.11%
44.35
Research And Development
24.97
+50.92%
16.54
-11.05%
18.60
+5.38%
17.65
Selling General And Administration
26.02
+17.30%
22.18
-3.75%
23.05
-13.69%
26.70
Selling And Marketing Expense
4.17
+1.83%
4.09
+24.70%
3.28
-36.31%
5.16
General And Administrative Expense
21.85
+20.80%
18.09
-8.48%
19.77
-8.28%
21.55
Salaries And Wages
9.86
+8.33%
9.10
-1.35%
9.23
-16.50%
11.05
Other Gand A
11.48
+40.53%
8.17
-15.43%
9.66
-2.12%
9.87
Total Expenses
56.62
+33.16%
42.52
-2.66%
43.68
-5.80%
46.37
Operating Income
-45.11
-46.31%
-30.83
+9.11%
-33.92
+1.44%
-34.41
Total Operating Income As Reported
-45.91
-48.90%
-30.83
+10.09%
-34.29
+0.36%
-34.41
EBITDA
-51.73
-41.09%
-36.66
-10.66%
-33.13
+0.75%
-33.38
Normalized EBITDA
-42.86
-50.81%
-28.42
+9.29%
-31.33
-0.51%
-31.17
Reconciled Depreciation
2.20
-6.62%
2.36
-1.26%
2.39
+4.19%
2.29
EBIT
-53.93
-38.21%
-39.02
-9.86%
-35.52
+0.43%
-35.67
Total Unusual Items
-8.87
-7.58%
-8.24
-358.03%
-1.80
+18.49%
-2.21
Total Unusual Items Excluding Goodwill
-8.87
-7.58%
-8.24
-358.03%
-1.80
+18.49%
-2.21
Special Income Charges
-2.60
-308.76%
1.25
-62.57%
3.33
+252.08%
-2.19
Other Special Charges
1.80
+244.50%
-1.25
+66.32%
-3.70
-269.04%
2.19
Impairment Of Capital Assets
0.80
0.00
-100.00%
0.37
0.00
Net Income
-53.43
-38.82%
-38.49
+6.80%
-41.30
+12.97%
-47.45
Pretax Income
-54.00
-37.57%
-39.25
+6.32%
-41.90
+13.42%
-48.40
Net Non Operating Interest Income Expense
-0.07
+71.00%
-0.23
+96.38%
-6.38
+49.84%
-12.72
Interest Expense Non Operating
0.07
-71.00%
0.23
-96.38%
6.38
-49.84%
12.72
Net Interest Income
-0.07
+71.00%
-0.23
+96.38%
-6.38
+49.84%
-12.72
Interest Expense
0.07
-71.00%
0.23
-96.38%
6.38
-49.84%
12.72
Other Income Expense
-8.82
-7.73%
-8.19
-412.13%
-1.60
-27.21%
-1.26
Other Non Operating Income Expenses
0.04
-15.69%
0.05
-74.50%
0.20
-78.95%
0.95
Gain On Sale Of Security
-6.27
+33.94%
-9.48
-85.07%
-5.12
-25525.00%
-0.02
Tax Provision
0.00
0.00
0.00
0.00
Tax Rate For Calcs
0.00
0.00
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-54.00
-37.57%
-39.25
+6.32%
-41.90
+13.42%
-48.40
Net Income From Continuing Operation Net Minority Interest
-53.43
-38.82%
-38.49
+6.80%
-41.30
+12.97%
-47.45
Net Income From Continuing And Discontinued Operation
-53.43
-38.82%
-38.49
+6.80%
-41.30
+12.97%
-47.45
Net Income Continuous Operations
-54.00
-37.57%
-39.25
+6.32%
-41.90
+13.42%
-48.40
Minority Interests
0.56
-25.82%
0.76
+26.29%
0.60
-36.13%
0.94
Normalized Income
-44.57
-47.33%
-30.25
+23.41%
-39.50
+12.70%
-45.25
Net Income Common Stockholders
-53.58
-39.18%
-38.49
+6.80%
-41.30
+12.97%
-47.45
Otherunder Preferred Stock Dividend
—
—
—
—
Diluted EPS
-22.97
+82.42%
-130.69
+95.12%
-2,678.17
+91.79%
-32,614.43
Basic EPS
-22.97
+82.42%
-130.69
+95.12%
-2,678.17
+91.79%
-32,614.43
Basic Average Shares
2.33
+691.90%
0.29
+1809.95%
0.02
+959.86%
0.00
Diluted Average Shares
2.33
+691.90%
0.29
+1809.95%
0.02
+959.86%
0.00
Diluted NI Availto Com Stockholders
-53.58
-39.18%
-38.49
+6.80%
-41.30
+12.97%
-47.45
Depreciation Amortization Depletion Income Statement
1.86
+0.98%
1.84
—
—
Depreciation And Amortization In Income Statement
1.86
+0.98%
1.84
—
—
Preferred Stock Dividends
0.14
—
—
—
Rent And Landing Fees
0.51
-37.45%
0.82
-6.84%
0.88
+39.43%
0.63
Rent Expense Supplemental
0.51
-37.45%
0.82
-6.84%
0.88
+39.43%
0.63
Total Other Finance Cost
—
—
—
—
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
38.32
-28.27%
53.42
+5.24%
50.76
+6.98%
47.45
Current Assets
20.34
-36.81%
32.20
+15.15%
27.96
+25.28%
22.32
Cash Cash Equivalents And Short Term Investments
0.97
-87.90%
8.00
+23.70%
6.47
+18.28%
5.47
Cash And Cash Equivalents
0.97
-87.90%
8.00
+23.70%
6.47
+18.28%
5.47
Cash Financial
0.97
-87.90%
8.00
+23.70%
6.47
+18.28%
5.47
Receivables
1.70
+3.10%
1.65
-24.59%
2.18
-11.47%
2.47
Accounts Receivable
1.52
-0.39%
1.53
-22.37%
1.97
+4.68%
1.88
Other Receivables
0.18
+47.50%
0.12
-44.70%
0.22
-63.10%
0.59
Inventory
8.60
-16.88%
10.35
+12.58%
9.19
+30.82%
7.02
Raw Materials
2.04
+10.32%
1.85
-10.06%
2.06
-2.09%
2.10
Work In Process
7.24
-2.31%
7.41
+13.66%
6.52
+81.08%
3.60
Finished Goods
1.32
+21.51%
1.09
+76.91%
0.61
-53.55%
1.32
Prepaid Assets
—
—
—
—
Restricted Cash
6.86
0.00
—
—
Other Current Assets
2.22
-81.84%
12.20
+20.58%
10.12
+37.49%
7.36
Total Non Current Assets
17.98
-15.31%
21.23
-6.90%
22.80
-9.28%
25.13
Net PPE
1.46
+4.50%
1.40
-16.27%
1.67
-1.47%
1.70
Gross PPE
2.02
+5.65%
1.91
-10.48%
2.14
+1.71%
2.10
Accumulated Depreciation
-0.56
-8.77%
-0.51
-10.32%
-0.47
-15.10%
-0.40
Properties
0.00
0.00
0.00
0.00
Land And Improvements
0.40
+0.00%
0.40
+0.00%
0.40
+0.00%
0.40
Buildings And Improvements
0.95
+16.48%
0.82
-16.60%
0.98
—
Machinery Furniture Equipment
0.19
-12.22%
0.22
-21.63%
0.28
+220.45%
0.09
Other Properties
0.48
+0.00%
0.48
+0.00%
0.48
-70.50%
1.62
Goodwill And Other Intangible Assets
16.02
-13.30%
18.48
-8.14%
20.12
-10.35%
22.44
Other Intangible Assets
16.02
-13.30%
18.48
-8.14%
20.12
-10.35%
22.44
Other Non Current Assets
0.49
-63.35%
1.35
+33.20%
1.01
+1.71%
0.99
Total Liabilities Net Minority Interest
57.01
+21.48%
46.93
+2.32%
45.87
-6.03%
48.81
Current Liabilities
40.65
+106.32%
19.70
+40.87%
13.99
-53.90%
30.34
Payables And Accrued Expenses
12.85
+78.57%
7.20
-17.95%
8.77
-37.22%
13.97
Payables
8.79
+62.69%
5.40
+2.54%
5.27
-17.63%
6.39
Accounts Payable
8.69
+64.32%
5.29
+6.27%
4.97
-14.36%
5.81
Current Accrued Expenses
4.07
+126.32%
1.80
-48.75%
3.51
-53.75%
7.58
Total Tax Payable
0.10
-13.16%
0.11
-60.96%
0.29
-50.09%
0.58
Current Debt And Capital Lease Obligation
27.63
+123.98%
12.34
+136.57%
5.21
-68.14%
16.37
Current Debt
27.44
+127.94%
12.04
+147.34%
4.87
-69.36%
15.88
Other Current Borrowings
27.44
+127.94%
12.04
+147.34%
4.87
-69.36%
15.88
Current Capital Lease Obligation
0.19
-35.79%
0.30
-14.08%
0.35
-27.95%
0.48
Current Deferred Liabilities
0.17
+0.00%
0.17
0.00
—
Current Deferred Revenue
0.17
+0.00%
0.17
0.00
—
Other Current Liabilities
—
—
—
—
Total Non Current Liabilities Net Minority Interest
16.36
-39.92%
27.23
-14.59%
31.88
+72.61%
18.47
Long Term Debt And Capital Lease Obligation
15.97
-33.96%
24.19
-24.12%
31.88
+72.61%
18.47
Long Term Debt
15.08
-35.83%
23.50
-24.17%
30.99
+74.67%
17.74
Long Term Capital Lease Obligation
0.89
+30.03%
0.69
-22.57%
0.89
+22.21%
0.72
Non Current Deferred Liabilities
0.38
-30.92%
0.55
0.00
—
Non Current Deferred Revenue
0.38
-30.92%
0.55
0.00
—
Preferred Securities Outside Stock Equity
—
2.48
0.00
—
Stockholders Equity
-17.29
-337.32%
7.29
+46.85%
4.96
+855.10%
-0.66
Common Stock Equity
-19.77
-371.43%
7.29
+46.85%
4.96
+855.10%
-0.66
Capital Stock
2.49
0.00
0.00
0.00
Common Stock
0.00
0.00
0.00
0.00
Preferred Stock
2.48
0.00
0.00
0.00
Share Issued
4.18
+690.22%
0.53
+979.73%
0.05
+3263.71%
0.00
Ordinary Shares Number
4.18
+690.22%
0.53
+979.73%
0.05
+3263.71%
0.00
Additional Paid In Capital
380.97
+7.55%
354.23
+12.86%
313.86
+17.56%
266.97
Retained Earnings
-399.92
-15.42%
-346.48
-12.40%
-308.25
-15.47%
-266.95
Gains Losses Not Affecting Retained Earnings
-0.83
-78.37%
-0.47
+28.37%
-0.65
+4.12%
-0.68
Minority Interest
-1.40
-76.86%
-0.79
-1135.94%
-0.06
+90.84%
-0.70
Other Equity Adjustments
-0.83
-78.37%
-0.47
+28.37%
-0.65
+4.12%
-0.68
Total Equity Gross Minority Interest
-18.69
-387.77%
6.49
+32.61%
4.90
+461.14%
-1.36
Total Capitalization
-2.21
-107.17%
30.79
-14.37%
35.95
+110.42%
17.09
Working Capital
-20.31
-262.55%
12.49
-10.60%
13.98
+274.31%
-8.02
Invested Capital
22.75
-46.88%
42.83
+4.91%
40.82
+23.81%
32.97
Total Debt
43.61
+19.39%
36.53
-1.53%
37.09
+6.48%
34.84
Net Debt
41.55
+50.90%
27.54
-6.30%
29.39
+4.38%
28.16
Capital Lease Obligations
1.08
+10.05%
0.98
-20.18%
1.23
+2.15%
1.21
Net Tangible Assets
-33.31
-197.57%
-11.19
+26.14%
-15.15
+34.38%
-23.10
Tangible Book Value
-35.80
-219.77%
-11.19
+26.14%
-15.15
+34.38%
-23.10
Interest Payable
0.01
+25.00%
0.00
-99.44%
0.72
-86.90%
5.49
Inventories Adjustments Allowances
-2.00
0.00
—
—
Preferred Stock Equity
2.48
—
—
—
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-23.69
+19.39%
-29.38
+11.61%
-33.24
-0.42%
-33.10
Cash Flow From Continuing Operating Activities
-23.69
+19.39%
-29.38
+11.61%
-33.24
-0.42%
-33.10
Net Income From Continuing Operations
-54.41
-39.39%
-39.03
+6.77%
-41.87
+14.68%
-49.08
Depreciation Amortization Depletion
2.20
-6.62%
2.36
-1.26%
2.39
+4.19%
2.29
Depreciation
2.20
-6.62%
2.36
-1.26%
2.39
+4.19%
2.29
Depreciation And Amortization
2.20
-6.62%
2.36
-1.26%
2.39
+4.19%
2.29
Other Non Cash Items
0.15
-45.94%
0.28
-97.88%
13.38
+6.33%
12.58
Stock Based Compensation
0.83
-49.36%
1.64
-22.30%
2.11
-36.35%
3.32
Provisionand Write Offof Assets
2.00
0.00
—
—
Asset Impairment Charge
0.80
0.00
-100.00%
0.37
0.00
Operating Gains Losses
1.96
+277.15%
-1.11
+69.64%
-3.65
-266.71%
2.19
Gain Loss On Investment Securities
—
—
—
—
Unrealized Gain Loss On Investment Securities
6.27
-33.94%
9.48
+85.07%
5.12
+24304.76%
0.02
Change In Working Capital
16.51
+648.47%
-3.01
+72.88%
-11.10
-150.65%
-4.43
Change In Receivables
-0.04
-107.41%
0.53
+76.51%
0.30
+170.78%
-0.42
Changes In Account Receivables
0.01
-98.64%
0.44
+600.00%
-0.09
+48.24%
-0.17
Change In Inventory
-0.25
+78.03%
-1.16
+46.61%
-2.17
-1.93%
-2.12
Change In Prepaid Assets
10.67
+805.22%
-1.51
+69.81%
-5.01
-221.22%
-1.56
Change In Payables And Accrued Expense
5.40
+772.73%
-0.80
+78.92%
-3.81
-802.95%
0.54
Change In Accrued Expense
2.06
+281.79%
-1.13
+61.73%
-2.96
-720.83%
-0.36
Change In Payable
3.35
+920.12%
0.33
+138.36%
-0.85
-194.79%
0.90
Change In Account Payable
3.35
+920.12%
0.33
+138.36%
-0.85
-194.79%
0.90
Change In Other Working Capital
-0.17
-123.65%
0.72
—
—
Change In Other Current Assets
1.17
+449.11%
-0.34
-1876.47%
-0.02
+96.91%
-0.55
Change In Other Current Liabilities
-0.27
+39.69%
-0.45
-14.47%
-0.39
-25.08%
-0.32
Investing Cash Flow
-0.04
+82.25%
-0.23
0.00
+100.00%
-1.68
Cash Flow From Continuing Investing Activities
-0.04
+82.25%
-0.23
0.00
+100.00%
-1.68
Net PPE Purchase And Sale
-0.04
-156.25%
-0.02
0.00
+100.00%
-0.08
Purchase Of PPE
-0.04
-156.25%
-0.02
0.00
+100.00%
-0.08
Capital Expenditure
-0.04
+82.25%
-0.23
—
-1.68
Net Intangibles Purchase And Sale
0.00
+100.00%
-0.21
0.00
+100.00%
-1.60
Purchase Of Intangibles
0.00
+100.00%
-0.21
0.00
+100.00%
-1.60
Financing Cash Flow
23.67
-24.14%
31.20
-8.84%
34.23
+47.65%
23.18
Cash Flow From Continuing Financing Activities
23.67
-24.14%
31.20
-8.84%
34.23
+47.65%
23.18
Net Issuance Payments Of Debt
13.35
+13445.00%
-0.10
+0.00%
-0.10
-102.58%
3.88
Issuance Of Debt
13.45
0.00
0.00
-100.00%
3.98
Repayment Of Debt
-0.10
+0.00%
-0.10
+0.00%
-0.10
+0.00%
-0.10
Long Term Debt Issuance
13.45
0.00
0.00
-100.00%
3.98
Long Term Debt Payments
-0.10
+0.00%
-0.10
+0.00%
-0.10
+0.00%
-0.10
Net Long Term Debt Issuance
13.35
+13445.00%
-0.10
+0.00%
-0.10
-102.58%
3.88
Net Common Stock Issuance
8.60
-73.05%
31.91
-0.59%
32.10
+56.88%
20.46
Proceeds From Stock Option Exercised
—
0.00
-100.00%
1.24
0.00
Net Other Financing Charges
-0.65
-7.24%
-0.61
-260.00%
0.38
+132.87%
-1.16
Changes In Cash
-0.06
-103.59%
1.59
+61.12%
0.98
+108.49%
-11.60
Effect Of Exchange Rate Changes
-0.11
-109.26%
-0.05
-460.00%
0.01
-6.25%
0.02
Beginning Cash Position
8.00
+23.70%
6.47
+18.28%
5.47
-67.93%
17.05
End Cash Position
7.83
-2.12%
8.00
+23.70%
6.47
+18.28%
5.47
Free Cash Flow
-23.73
+19.88%
-29.61
+10.91%
-33.24
+4.42%
-34.78
Interest Paid Supplemental Data
0.02
+57.14%
0.01
-60.00%
0.04
+52.17%
0.02
Common Stock Issuance
8.60
-73.05%
31.91
-0.59%
32.10
+56.88%
20.46
Earnings Losses From Equity Investments
0.16
+17.39%
0.14
+170.59%
0.05
0.00
Issuance Of Capital Stock
10.98
-65.60%
31.91
-2.45%
32.71
+59.86%
20.46
Net Preferred Stock Issuance
2.38
0.00
-100.00%
0.61
0.00
Preferred Stock Issuance
2.38
0.00
-100.00%
0.61
0.00
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category